A new paper by the Institute for Clinical and Economic Review (ICER) looks at the cost-effectiveness versus affordability ...

Like tens of thousands of Massachusetts residents, community college professor Carolyn McGrath has been paying for medicine ...

Orforglipron, which could become the first GLP-1 pill — a much more convenient option — is a step closer to hitting the ...

Opinion: McDermott, Will & Emery's Byron Kalogerou and Meredith Cullen Schwartz say demand in the anti-obesity market and new ...

The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed ... against improving accessibility and affordability of GLP-1 medications going ...

Mass General Brigham researchers found that by December 2023, more than 1 in 3 of the medications being started for type 2 diabetes treatment were GLP-1RA-based medications, such as semaglutide or tir ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Felix. In this article, we will summarize the bulls’ ...

The senator urged President Trump to reverse his decision to pull a Biden-era proposal that would have made GLP-1 medications more affordable ... version of the drug, Zepbound, which uses the ...

Zepbound is an alternative option to Mounjaro, which people may want to consider if there are supply issues. Like Calibrate, Ro Body is a personalized weight loss plan that offers coaching.

In a step towards making the drugs more affordable, Eli Lilly announced that its weight loss drug, Zepbound ... the researchers identified issues with both the packaging and the ingredients.

Bristol-Myers Squibb's (BMY) Reblozyl, a rival of Rytelo in the MDS space, earned >$1.7bn of revenues in 2024, which may imply that, if Geron can solve its short-term demand issues, which it puts ...

It announced it would make GLP-1 injections available to its customers at very affordable costs ... a challenge to an FDA declaration saying Zepbound, another weight loss drug using tirzepatide ...